- Home
- VTVT
as 12-18-2024 1:43pm EST
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HIGH POINT |
| Market Cap: | 31.9M | IPO Year: | 2015 |
| Target Price: | $35.00 | AVG Volume (30 days): | 30.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.38 - $30.99 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,000,000 | Revenue Growth: | 11011.11% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of vTv Therapeutics Inc. (VTVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SEKHRI PAUL J | VTVT | Pres, CEO and Exec Chairperson | Nov 15 '24 | Buy | $16.73 | 5,000 | $83,811.94 | 1,378 |
Latest vTv Therapeutics Inc. News
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
GlobeNewswire
16 days ago
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
Simply Wall St.
a month ago
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%
Associated Press Finance
a month ago
VTv Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
a month ago
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
TipRanks
2 months ago
vTv Therapeutics Faces License Agreement Termination
Simply Wall St.
4 months ago
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate
Associated Press Finance
4 months ago
VTv Therapeutics: Q2 Earnings Snapshot
Compare VTVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.